Latest developments in the treatment of HIV with Vorinostat

Vorinostat (Vorinostat) is a drug approved by the U.S. Food and Drug Administration (FDA) for the treatment of cancer under the trade name Zolinza and belongs to a group of drugs called latency reversal agents. Vorinostat is being studied as a potentialHIV latency reversal agent (LRA) as part of an investigational treatment strategy known as "shock and kill." Vorinostat has been shown to reactivate HIV in latently infected HIV-infected T cells both in vitro and in vivo.

Currently, there is no cure for HIV infection. One of the major obstacles to curing HIV infection is that the virus can hide and be inactivated (latent) in certain cells of the immune system, such as resting CD4 cells, for many months or even years. The cells where latent HIV hides are called latent HIV reservoirs. Latency reversal agents work by pulling HIV out of latency in dormant CD4 cells. Once latent HIV is reactivated, the virus-carrying CD4 cells are more likely to be recognized and killed by the body's immune system, or may be killed by certain HIV therapies, such as those that enhance the body's immune response to HIV.

The original drug of vorinostat is not currently on the market in China, and therefore cannot be included in the national medical insurance coverage. Overseas, there is an American version of the original drug, specifications100mg*120 pills per box, which may cost around 100,000 yuan (the price may fluctuate due to exchange rate effects). It is very expensive, and there is currently no generic version of vorinostat produced and launched. For more drug information and specific prices, please consult a medical consultant.